drugset / Trial / NCT04745910
Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome
NaSingle-groupOpen-labelTreatment
Summary
This trial studies the effect of pegloticase in reducing uric acid levels in patients with hyperuricemia (high blood levels of uric acid) caused by tumor lysis syndrome. Tumor lysis syndrome occurs when the breakdown products of cancer cells, such as uric acid, enter the blood stream. High levels of uric acid in blood may cause kidney damage and reduce kidney function. The goal of this trial is to learn if pegloticase may lower uric acid levels in blood when given to cancer patients with hyperuricemia caused by tumor lysis syndrome.
Timeline
- Start
- 2022-04-05
- Primary completion
- 2026-04-27
- Completion
- 2026-04-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pegloticase | Protein / enzyme biologic | — | Intravenous |
| Background | Rasburicase | Protein / enzyme biologic | — | Intravenous |